. About one-fifth of the patients, however, were unassessable owing to marker levels within the normal range and substantial proportions of patients showed a significant marker decrease during disease progression or a marker increase despite an objective tumour response, indicating that the correlation between these epithelial tumour markers and treatment response is far from perfect.
Response evaluation in bone metastases from breast carcinoma is notoriously difficult (Blomqvist et al., 1987) . Serum tumour markers, such as CEA and Ca 15-3, may sometimes be useful. In the study by Robertson et al. of 65 breast cancer patients treated with endocrine therapy the diagnostic accuracy of CEA and Ca 15-3 for response assessment 4 and 6 months after the start of treatment was higher than 80% (Robertson et al., 1991) . About one-fifth of the patients, however, were unassessable owing to marker levels within the normal range and substantial proportions of patients showed a significant marker decrease during disease progression or a marker increase despite an objective tumour response, indicating that the correlation between these epithelial tumour markers and treatment response is far from perfect.
Radiological assessment of the treatment response in skeletal metastases is based on assessing the reaction of bone tissue to metastatic activity rather than measuring the tumour size itself. An intriguing possibility would therefore be to use biochemical markers of bone metabolism as indicators of treatment response in the skeleton. Unfortunately, the conventional markers of skeletal metabolism like serum calcium (sCa), urinary calcium excretion (uCa), urinary hydroxyproline excretion (OHP), urinary excretion of collagen pyridinoline cross-links, alkaline phosphatase (AP) or osteocalcin (gla), are relatively unspecific. Urine collection is, moreover, often cumbersome in clinical practice. Since type I collagen is the most common protein in the skeleton, comprising about 90% of the organic matrix in bone tissue (Melkko et al., 1990) assays of the turnover of this protein should be good markers of bone turnover. An assay of the breakdown of mature type I collagen ICTP, developed by Risteli et al. 1993 , has recently been shown to be a sensitive marker of bone resorption in disorders as different as rheumatoid arthritis, multiple myeloma and prostatic carcinoma Hakala et al., 1993; Kylmala et al., 1993) . The synthesis of type I collagen can be measured by the carboxy-terminal propeptide of type Correspondence: C Blomqvist Received 3 January 1995; revised 7 June 1995; accepted 23 November 1995 I procollagen, PICP (Melkko et al., 1990) , which generally has shown good correlation with bone formation in a variety of metabolic and malignant disorders.
We report here the association between changes in the serum concentrations of these collagen metabolites and treatment response in 36 patients with bone metastases from breast carcinoma treated within a controlled trial investigating the effect of salmon calcitonin. Details of this study have been published previously (Blomqvist et al., 1988) . Calcitonin had no discernible effect on bone metastases or bone turnover monitored by skeletal radiograph, scintigraphy and biochemical markers of bone formation (AP, gla), resorption (OHP) or the balance between these (uCa, sCa). We have previously reported a correlation between the concentration of the amino-terminal propeptide of type III collagen, PIIINP, in serum and the treatment response in the same patient material (Blomqvist et al., 1987) . PIIINP reflects synthesis of type III collagen, which occurs together with type I collagen in non-mineralised connective tissue, especially in newly formed connective tissue, e.g. healing wounds, stroma of malignant tumours or the bone marrow at metastatic invasion.
Patients and methods
Fifty normocalcaemic female patients with painful bone metastases from breast cancer (documented on skeletal radiographs and radionuclide scans) were randomly allocated to calcitonin and placebo treatment. Thirty-six of these had serum available for assessment of the collagen markers. Three patients also had pulmonary metastases, two skin metastases and one a malignant pleural effusion. All other patients had skeletal disease exclusively. The patient characteristics are summarised in Table I months of the trial. Moreover, the patients were required to have been on the same treatment regimen for at least 3 months before the start of the study. The first assessment at 3 months of trial therefore reflected response evaluation after at least 6 months on the same therapy.
Biochemical measurements were performed at the start of the study, at month 1 and month 3. All serums were sampled between 08.00 and 10.00 h, and stored at -20°C. The antigens recognised by the antibodies to collagen metabolites are known to be stable for several years under these storage conditions (L Risteli, unpublished observation). ICTP and PICP were investigated from thawed serum in 1994, all other measurements were performed shortly after conclusion of the calcitonin study in 1986. One patient had missing values for collagen metabolites (ICTP, PICP and PIIINP) at 3 months' evaluation. Osteocalcin values were missing in two patients at baseline and one further patient had an unmeasurably low level at baseline. Cases with missing laboratory values were excluded from those analyses only where these values were needed. Bone scans and radiographs were performed at baseline and month 3. All radiographs were reviewed by one of us (PV). The response to treatment was assessed by UICC criteria (Hayward et al., 1977) . Urine was collected for 2 h after an overnight fast and measured for calcium, creatinine and hydroxyproline. The serum measurements included alkaline phosphatase (a spectrophotometric assay), osteocalcin (Price and Nishimoto, 1980) and collagen metabolite assays. The methods for the PICP and ICTP assays have been described previously (Melkko et al., 1990; Risteli et al., 1993) . ICTP and PICP reflects degradation and synthesis, respectively, of type I collagen, the predominant collagen in bone matrix. The reference interval of ICTP for adult women is 1.7 -4.6 jug 1'-, and that of PICP is 50 -170 jig 1 -'. The intra-and inter-assay coefficients of variation are 2.1-3.7% and 3.6 -6.6% for PICP, and 2.8 -6.2% and 4.1-7.9% for ICTP, respectively.
The differences in marker values between patients with or without soft-tissue metastases and the effect of calcitonin treatment on marker change were tested with the MannWhitney test. The correlations between marker levels and the number of metastases and between changes in marker levels and the treatment response were assessed by Spearman's rank-order correlation coefficient (rs). The correlation between baseline collagen metabolite levels and subsequent treatment response was calculated with the exact trend test (Statxact, 1992 (non-progressors) . Confidence intervals (95%) for kappa and rs were calculated with the CIA statistical software .
Results
Baseline levels of type I collagen metabolites The median concentration of ICTP in serum at baseline was 6.1 jig 11 (range 1.6-18.8 jig 11). The ICTP value was above the reference interval in 23 patients (64%) altogether, 4/9 (44%) of the patients later showing a progressive disease at the 3 months evaluation, 12/18 (67%) with a stable disease and 7/9 (78%) of the patients with a partial response (P = 0.23, exact trend-test). The ICTP values were above the reference interval in 18/30 (60%) patients with bone metastases only, in 2/2 with skin metastases and in all three patients with lung metastases. The only patient with pleural metastases had a normal ICTP value. There was no statistically significant difference (P = 0.14, Mann -Whitney) in ICTP serum concentration at baseline in the patients with (median ICTP 11.1 jIg 1-l) or without (median 5.65 Mg 1-') soft-tissue metastases.
The median PICP value at baseline was 119 jig 1`(range 63-373 jg 11). PICP was above the reference interval in nine patients (25%), 1/9 (11%) of those showing progressive disease at the 3 months evaluation, 4/18 (22%) with a subsequent stable disease and 4/9 (44%) of the patients with partial response (P = 0.18, exact trend test). High PICP values were encountered in 5/30 (17%) of the patients with bone metastases only, in 1/2 with skin metastases and in all three patients with lung metastases. PICP value was normal in the patient with pleural metastases. The difference in baseline PICP concentrations between the patients without (median PICP 114 jg 1-1) and those with (median 254 jg 1-') softtissue metastases was statistically significant (P=0.016, Mann-Whitney).
There Correlation between changes in biochemical markers of bone metabolism and the treatment response The Spearman's rank-order correlation coefficients between the changes observed in the markers from baseline to 3 months from the start of this study and the response to treatment are shown in Table III . There was a highly significant correlation between ICTP change from baseline , 1993) . Although the bone metastases in prostatic carcinoma tend to be osteoblastic rather than lytic, histomorphometric investigations have demonstrated that presence of prostatic cancer cells in the bone leads to both increased degradation and synthesis of bone, even if the net balance often results in increased sclerosis (Taube et al., 1994) . PICP, which reflects synthesis of type I collagen is low or normal in multiple myeloma, but often high in prostatic carcinoma metastatic to the skeleton Kylmala et al., 1993) .
In the present study, the metabolites of type I collagen breakdown and synthesis tended to increase in concert, reflecting the fact that breast cancer cells in the bone marrow simultaneously increased both the synthesis and degradation of bone. Both ICTP and PICP also showed significant positive correlations with both hydroxyproline excretion in the urine and the activity of alkaline phosphatase in serum. In this respect bone metastases from breast cancer resemble prostatic carcinoma more than multiple myeloma. The frequency of high PICP values, however, was only 24% in this study, compared to about 60% in a study of prostatic carcinoma (Kylmala et al., 1993) , probably reflecting the lower bone formation activity in bone metastases from breast carcinoma.
Surprisingly the correlation between collagen metabolism and urinary calcium excretion was negative. It is possible that humoral mediators excreted by mammary carcinoma cells e.g. PTHrp, a peptide inhibiting the excretion of calcium in the urine, modify calcium handling by the kidneys (Bonjour et al., 1988) , making calcium excretion an unreliable indicator of skeletal metabolism in this disease. If this is the case, however, serum calcium should increase more with increased bone resorption than if calcium handling by the kidneys were unaffected by the carcinoma. In fact there was no correlation between serum calcium and the indicators of type I collagen metabolism. Thus, the most probable explanation for the failure of calcium excretion to behave as a marker of metastatic activity in the skeleton is that the coupling of bone resorption and formation was retained with a slight surplus of bone formation in most patients. As urinary calcium excretion reflects the balance between bone mineralisation and resorption rather than skeletal turnover, it is conceivable that it should be a poor marker of metastatic activity in the skeleton. The same consideration should also hold for serum calcium, which as expected showed no correlation with treatment response or type I collagen turnover.
Both ICTP and PICP showed a positive correlation with metastatic activity, as reflected by the association between these markers and the number of skeletal metastases and by significant correlations with the treatment response. ICTP seemed to be the more reliable indicator of the two metabolites, as expected, since bone lysis should be more closely associated with collagen breakdown than with its synthesis. The diagnostic accuracy of both ICTP and PICP in assessing the treatment response was at the same level as published results on classical tumour markers Ca 15-3 and CEA (Robertson et al., 1991) .
Most biochemical markers behaved similarly in responding and stable patients. These two groups on the other hand, differed significantly from the progressors with respect to the changes in ICTP and PICP levels. The only marker that showed any difference between a partial response and a stable disease was AP, which seemed to decrease more in the responding than in the stable patients. The inability of the type I collagen metabolites to distinguish between responding and stable patients should not be seen as a major drawback, since patients with stable skeletal metastases from mammary carcinoma have as favourable a prognosis as the responding patients (Bitran et al., 1980; Blomqvist et al., 1987) , and should probably be managed as responders.
In a previous study on the same patient material we have reported that PIIINP, a metabolite reflecting the synthesis of type III collagen, also correlated with metastatic activity (Blomqvist et al., 1987) . There was in fact a significant correlation between the concentrations of PIIINP and those of both ICTP and PICP. PIIINP is a peptide formed during the synthesis of type III collagen, which occurs in most nonmineralised connective tissues together with type I collagen. High values of PIIINP have been found in gynaecological malignancies (Kauppila et al., 1989; Tomas et al., 1990 Tomas et al., , 1991 (Coombes et al., 1983) . Further studies should be done to clarify whether ICTP and PICP are less reliable for the assessment of treatment response within the first few months of treatment. Another weakness of this study was the heterogeneity in the treatment schedules given to the patients, which makes it impossible to study potential interactions between marker levels and treatment itself. It has been shown previously (Wiklund et al., 1993 ) that chemotherapy per se increases type III collagen turnover and PIHNP. The effect of chemotherapy on the PIIINP level was, however, relatively small, on average a 13% increase during 100 days of treatment. Whether chemotherapy has an impact on ICTP and PICP levels is presently unknown.
Metabolites of type I collagen degradation and biosynthesis, in particular the degradation marker ICTP, seem to correlate with disease activity of breast cancer metastatic to the skeleton. Thus, assessment of metabolism of type I collagen could be an alternative to the use of conventional tumour markers in the monitoring of skeletal metastases from breast carcinoma.
